These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17135727)

  • 1. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change. Analysis of subscale items and 'clinician's impression'.
    Nakamura Y; Homma A; Kobune S; Tachibana Y; Satoh K; Takami I; Nagai S; Sakai M; Fukuta H; Matsuda H; Hashimoto H; Kusunoki T;
    Dement Geriatr Cogn Disord; 2007; 23(2):104-15. PubMed ID: 17135727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change.
    Homma A; Nakamura Y; Kobune S; Haraguchi H; Kodani N; Takami I; Matsuoka J; Matsuda H; Kusunoki T
    Dement Geriatr Cogn Disord; 2006; 21(2):97-103. PubMed ID: 16352896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale.
    Auer SR; Monteiro IM; Reisberg B
    Int Psychogeriatr; 1996; 8(2):247-66. PubMed ID: 8994895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil.
    Samara M; Levine SZ; Yoshida K; Goldberg Y; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furakawa TA
    J Alzheimers Dis; 2021; 82(3):1075-1084. PubMed ID: 34120898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
    Suh GH; Yeon Jung H; Uk Lee C; Hoon Oh B; Nam Bae J; Jung HY; Ju YS; Kil Yeon B; Park J; Hong I; Choi S; Ho Lee J;
    Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.
    Nakamura Y; Imai Y; Shigeta M; Graf A; Shirahase T; Kim H; Fujii A; Mori J; Homma A
    Dement Geriatr Cogn Dis Extra; 2011 Jan; 1(1):163-79. PubMed ID: 22163242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses.
    Okuizumi K; Kamata T; Matsui D; Saito K; Matsumoto T; Fukuchi Y
    Expert Opin Pharmacother; 2018 Apr; 19(5):425-430. PubMed ID: 29448852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Stanley J; Howlett SE; Dunn T; Rockwood K
    Alzheimers Dement; 2021 May; 17(5):856-865. PubMed ID: 33928754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
    Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
    CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
    Schneider LS; Raman R; Schmitt FA; Doody RS; Insel P; Clark CM; Morris JC; Reisberg B; Petersen RC; Ferris SH
    Alzheimer Dis Assoc Disord; 2009; 23(3):260-7. PubMed ID: 19812469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of global change in Alzheimer's disease: identifying consensus.
    Olin JT; Schneider LS; Doody RS; Clark CM; Ferris SH; Morris JC; Reisberg B; Schmitt FA
    J Geriatr Psychiatry Neurol; 1996 Oct; 9(4):176-80. PubMed ID: 8970010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.